Results 71 to 80 of about 36,254 (205)

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial

open access: yesBJU International, Volume 135, Issue 4, Page 638-647, April 2025.
Objectives To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder. Patients and Methods This single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for ...
Meryam El Issaoui   +2 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto   +12 more
wiley   +1 more source

Rivaroxaban in atrial fibrillation

open access: yes, 2012
Mariano A Giorgi,1,2 Lucas San Miguel31Cardiology Service, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”, 2Department of Pharmacology, School of Medicine, Universidad Austral,
Giorgi MA, Miguel LS
core  

Do We Really Know How to Manage Anticoagulated Patients for Periodontal Nonsurgical Therapy? An Observational Cohort Study

open access: yesInternational Journal of Dental Hygiene, EarlyView.
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton   +5 more
wiley   +1 more source

Rivaroxaban [díptic]

open access: yes, 2018
Anticoagulants orals d’acció directa; Rivaroxaban; MedicamentsAnticoagulantes orales de acción directa; Rivaroxaban; MedicamentosDirect-acting oral anticoagulants; Rivaroxaban; MedicinesPreguntes i respostes sobre l’anticoagulant oral d’acció directa ...

core  

Refining Residual Ischemic Stroke Risk in Anticoagulated Atrial Fibrillation Using Index Outpatient LA Diameter: The CHA2DS2‐VALa Score

open access: yesJournal of Cardiovascular Electrophysiology, EarlyView.
In anticoagulated atrial fibrillation, residual ischemic stroke risk persists despite guideline‐directed therapy. In this single‐center cohort, an enlarged index outpatient left atrial diameter independently predicted stroke and improved risk stratification when added to CHA2DS2‐VA (CHA2DS2‐VALa), supporting a simple, clinically implementable ...
Sefa Erdi Ömür   +7 more
wiley   +1 more source

Case report: Severe hepatopathy following rivaroxaban administration in a dog

open access: yesFrontiers in Veterinary Science
Rivaroxaban, a specific factor Xa inhibitor and commonly utilized anticoagulant, has been known to cause hepatotoxicity and liver failure in humans. Although rivaroxaban is frequently used in veterinary medicine, hepatotoxicity has not been previously ...
Allison P. Mosichuk   +5 more
doaj   +1 more source

A Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin for Deep Vein Thrombosis (DVT) Treatment in Ethiopia

open access: yesClinicoEconomics and Outcomes Research, 2021
Manaye Tamrie Derseh,1 Kiflom Solomon,2 Wasihun Tamene,3 Wosenie Beneberu,3 Ashagrachew Tewabe Yayehrad,4 Abyou Seyfu Ambaye1 1Departement of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi ...
Derseh MT   +5 more
doaj  

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

open access: yesBMC Cardiovascular Disorders, 2020
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy